Camp4 Therapeutics Q3 EPS $(0.55) Beats $(0.68) Estimate, Sales $795.000K Beat $480.000K Estimate
Benzinga Newsdesk 11 months ago
EarningsEarnings BeatsNews
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) by 19.59 percent. This is a 97.73 percent increase over losses of $(24.19) per share
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) by 19.59 percent. This is a 97.73 percent increase over losses of $(24.19) per share from the same period last year. The company reported quarterly sales of $795.000 thousand which beat the analyst consensus estimate of $480.000 thousand by 65.63 percent.